PharmGen Science Inc (004720) - Total Liabilities
Based on the latest financial reports, PharmGen Science Inc (004720) has total liabilities worth ₩83.70 Billion KRW (≈ $56.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of PharmGen Science Inc to see how much of total assets are deployed in long-term investments.
PharmGen Science Inc - Total Liabilities Trend (2004–2024)
This chart illustrates how PharmGen Science Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of PharmGen Science Inc.
PharmGen Science Inc Competitors by Total Liabilities
The table below lists competitors of PharmGen Science Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AXIOS Sustainable Growth
NYSE:AXAC
|
USA | $1.18 Million |
|
Sand Nisko Capital Bhd
KLSE:7943
|
Malaysia | RM39.98 Million |
|
Mr Bricolage
PA:ALMRB
|
France | €207.68 Million |
|
Lustrum Minerals Limited
AU:LRM
|
Australia | AU$-153.34K |
|
Skyline Builders Group Holding Limited
NASDAQ:KAZR
|
USA | $2.62 Million |
|
Averbuch Formica Center Ltd
TA:AVER
|
Israel | ILA30.26 Million |
|
Elastron S.A. - Steel Service Centers
AT:ELSTR
|
Greece | €115.39 Million |
|
Haesung Optics Co. Ltd
KQ:076610
|
Korea | ₩131.31 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down PharmGen Science Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is PharmGen Science Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmGen Science Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmGen Science Inc (2004–2024)
The table below shows the annual total liabilities of PharmGen Science Inc from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩114.02 Billion ≈ $77.27 Million |
+5.86% |
| 2023-12-31 | ₩107.71 Billion ≈ $72.99 Million |
-2.33% |
| 2022-12-31 | ₩110.28 Billion ≈ $74.73 Million |
+18.08% |
| 2021-12-31 | ₩93.39 Billion ≈ $63.29 Million |
+79.69% |
| 2020-12-31 | ₩51.97 Billion ≈ $35.22 Million |
+18.69% |
| 2019-12-31 | ₩43.79 Billion ≈ $29.68 Million |
+5.91% |
| 2018-12-31 | ₩41.35 Billion ≈ $28.02 Million |
+137.26% |
| 2017-12-31 | ₩17.43 Billion ≈ $11.81 Million |
-37.52% |
| 2016-12-31 | ₩27.89 Billion ≈ $18.90 Million |
+56.78% |
| 2015-12-31 | ₩17.79 Billion ≈ $12.06 Million |
-18.86% |
| 2014-12-31 | ₩21.93 Billion ≈ $14.86 Million |
+41.51% |
| 2013-12-31 | ₩15.49 Billion ≈ $10.50 Million |
-7.27% |
| 2012-12-31 | ₩16.71 Billion ≈ $11.32 Million |
-30.76% |
| 2011-12-31 | ₩24.13 Billion ≈ $16.35 Million |
-27.74% |
| 2005-12-31 | ₩33.40 Billion ≈ $22.63 Million |
+35.90% |
| 2004-12-31 | ₩24.58 Billion ≈ $16.65 Million |
+1.67% |
| 2004-09-30 | ₩24.17 Billion ≈ $16.38 Million |
-- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more